Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of Tumor-Infiltrating Leukocytes in Endolymphatic Sac Tumor.
Laryngoscope
January 2025
Department of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, China.
Objective: Endolymphatic sac tumors (ELSTs), as rare low-grade neoplasms, are primarily treated with surgery. This study analyzes the characteristics of tumor-infiltrating leukocytes (TILs) in ELSTs and their relationships with clinical features to explore the potential for immunotherapy in ELSTs.
Methods: Clinical data and tumor specimens of 10 ELSTs patients who underwent surgery were retrieved.
Morphological studies of labyrinthine tissue in patients affected with Meniere's disease and vestibular schwannoma following labyrinthectomy.
Eur Arch Otorhinolaryngol
December 2024
ENT Department, Sydney Adventist Hospital, Sydney, NSW, Australia.
Background: Meniere's disease (MD) is a disabling disease of the inner ear, having a substantial effect on a patient's quality of life. While various postulations regarding its aetiology exists, due to the difficulty with accessing inner ear tissue, there have been limited histological studies in patients with active MD.
Methods: Tissue was collected during labyrinthectomy from 8 patients with intractable MD who had failed medical therapy (22 samples), and 9 patients undergoing translabyrinthine resection of vestibular schwannoma (19 samples).
Revisit to Endolymphatic Duct Identification Using Middle Cranial Fossa Dural Plate: A Novel Technique.
Cureus
November 2024
Otolaryngology - Head and Neck Surgery, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, IND.
Objectives: Surgical treatments for Ménière's disease differ in efficacy. Endolymphatic duct blockage (EDB) is favored for its minimal risk and ability to preserve hearing. One of the main challenges in the technique is the difficulty in accurately identifying the endolymphatic duct (ED).
View Article and Find Full Text PDFIs the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel-Lindau?
J Kidney Cancer VHL
December 2024
Department of Urology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Article Synopsis
- The study explores the suitability of the TriNetX database for researching the real-world management of Von Hippel-Lindau (vHL), a rare hereditary disease characterized by various tumors.
- The researchers analyzed data from 1,232 patients diagnosed with vHL within the TriNetX database to identify the prevalence of several vHL-related conditions, finding that certain conditions like renal cell carcinoma and pheochromocytomas were more common than others.
- Despite the robust patient data available, the findings suggest that vHL and its associated conditions may be underdiagnosed within the TriNetX database, casting doubt on its effectiveness for comprehensive vHL studies compared to existing literature.
Comparative Proteomic Analysis of Endolymphatic Sac Luminal Fluid in Patients with Meniere's Disease and Controls.
J Inflamm Res
December 2024
Department of Anesthesiology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Article Synopsis
- Meniere's disease (MD) is linked to problems with the endolymphatic sac (ES), but the specific molecular causes are still unclear.
- A study compared the proteins in ES luminal fluids from MD patients and healthy controls, identifying significant differences—6 proteins were found to be expressed differently, with some increased and others decreased in MD patients.
- The findings suggest that certain proteins indicate inflammation and oxidative damage in MD, and one protein, CD44, might be connected to the overproduction of endolymph in the condition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!